Company Profile

Valentis Inc (AKA: Megabios Corporation~Genemedicine Inc)
Profile last edited on: 2/27/2019      CAGE:       UEI:

Business Identifier: Non-viral gene-based therapies
Year Founded
1992
First Award
1993
Latest Award
2000
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

863-A Mitten Road
Burlingame, CA 94010
   (650) 697-1900
   info@valentis.com
   www.valentis.com
Location: Multiple
Congr. District: 14
County: San Mateo

Public Profile

A complex story to some extent indicative of the early years of Biotech. The merger of Megabios Corporation and GeneMedicine, Inc. in March 1999 originally formed Valentis Inc. (NASDAQ:VLTS), based in Burlingame, CA and addressing development of procducts for peripeheral arterial disease. Organized around development of gene medicine biopharmaceuticals, at the time Vanetis had three product platforms for the development of novel therapeutics: the gene medicine, GeneSwitch and DNA vaccine platforms, Valentis had developed synthetic vaccine delivery systems based on several classes of polymers and had proprietary PINC (polymeric, non-condensing) polymer-based delivery technologies for intramuscular administration providing for higher and more consistent levels of antigen production. In 2006 San Diego based Inivio Biomedical (developing late-stage cancer therapies) acquired from Valentis its gene regulation, a synthetic gene delivery system, some catioic lipids and some expression technologies. In October of the same year, Valentis signed a merger agreement with Urigen Inc - also based in Burlingame. The latter firm took over the VLTS, shifted trading to OTC and ceasd trading in June 2007.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : VLTS
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2000 1 NIH $107,000
Project Title: Anionic Liposomes for Gene Delivery to APCS
2000 1 NIH $99,160
Project Title: Systemic Anti-Angiogenesis Gene Therapy for Brain Tumors
2000 1 NIH $102,720
Project Title: DNA Condensation For Improved Stability And Expression
1999 2 NIH $767,260
Project Title: Construction of Synthetic Muscle Specific Promoters
1999 1 NIH $104,431
Project Title: Construction Of Plasmids With Improved Expression Duration For Cancer

Key People / Management

  Benjamin McGraw III -- CEO

  Hector W Alila

  Eric Eastman

  Cornelia Gorman

  Petrak Karel

  Fred D Ledley

  Jeffrey L Nordstrom

  Jacqueline S Papkoff

  Rodney Pearlman -- VP R&D

  Alain Rolland

Company News

There are no news available.